Adhirons are efficient tools to guide antiviral ligand discovery
Adhirons are small, antibody-like proteins expressed in bacteria that bind to biological targets with high affinity. Since their discovery, Adhirons have been isolated against over 350 targets, and they can be used for many research applications. However, their therapeutic application is at present in its early stages, hence the interest in developing novel small molecules to mimic their effect. We develop a pipeline for small molecule discovery where Adhirons act as starting templates in a ligand-based virtual screening workflow. For proof of concept, we use Adhirons against two viral systems: Crimean-Congo Haemorrhagic Fever Virus and Influenza A Virus. In both cases, a hit was identified from the mimics using biophysical and cell-based assays, highlighting how Adhirons, commercial libraries and structural approaches can be combined to accelerate small molecule inhibitor discovery of viruses.
Authors
- Oliver Debski-Antoniak (ORCID: https://orcid.org/0000-0001-8239-2738)
- alex derry (ORCID: https://orcid.org/0000-0003-2978-2192)
- Juan Fontana (ORCID: https://orcid.org/0000-0002-9084-2927)
- Katie J. Simmons (ORCID: https://orcid.org/0000-0003-4846-9097)
- Alex J. Flynn (ORCID: https://orcid.org/0000-0002-9370-0879)
- Stephen P. Muench (ORCID: https://orcid.org/0000-0001-6869-4414)
Institutions
- University of Leeds (GB)
- University of the Basque Country (ES)
- Utrecht University (NL)
- New York Structural Biology Center (US)
- Fundación Biofísica Bizkaia (ES)
- Leeds Beckett University (GB)
Publication Details
- Journal
- Communications Biology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1038/s42003-025-09137-x
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- University of Leeds
- Medical Research Council
- European Regional Development Fund
- Agencia Estatal de Investigación